MétaCan
Menu
Back to cohort
Record W4298001471 · doi:10.1186/s12902-022-01140-1

Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom

2022· article· en· W4298001471 on OpenAlexafffundabout
Vanessa C. Brunetti, Audray St-Jean, Sophie Dell’Aniello, Anat Fisher, Oriana Hoi Yun Yu, Shawn Bugden, Jean-Marc Daigle, Nianping Hu, Silvia Alessi‐Severini, Baiju R. Shah, Paul E. Ronksley, Lisa M. Lix, Pierre Ernst, Kristian B. Filion, Samy Suissa, Colin R. Dormuth, Brenda R. Hemmelgarn, Jacqueline Quail, Dan Château, J. Michael Paterson, Jacques LeLorier, Adrian R. Levy, Robert W. Platt, Ingrid Sketris

Bibliographic record

VenueBMC Endocrine Disorders · 2022
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsDalhousie UniversityUniversité de MontréalUniversity of CalgaryHealth Sciences CentreJewish General HospitalSunnybrook Health Science CentreSaskatchewan Health Quality CouncilInstitut National d'Excellence en Santé et en Services SociauxUniversity of ManitobaMemorial University of NewfoundlandUniversity of British ColumbiaMcGill University Health CentreInstitute for Clinical Evaluative SciencesMcGill UniversityCentre Hospitalier de l’Université de MontréalManitoba Health
FundersFonds de Recherche du Québec - SantéCanadian Institutes of Health ResearchMcGill University
KeywordsMedicineCohortDiabetes mellitusGlucagon-like peptide-1Coronary artery diseaseType 2 diabetesInternal medicineFirst lineCohort studyPharmacologyEndocrinology

Abstract

fetched live from OpenAlex

BACKGROUND: line antidiabetic drugs in a real-world setting are poorly understood. We described the characteristics of new users of sodium-glucose co-transporter-2 inhibitors (SGLT-2i), dipeptidyl peptidase-4 inhibitors (DPP-4i), and glucagon-like peptide-1 receptor agonists (GLP-1 RA) in Canada and the United Kingdom (UK) between 2016 and 2018. METHODS: We conducted a multi-database cohort study using administrative health databases from 7 Canadian provinces and the UK Clinical Practice Research Datalink. We assembled a base cohort of antidiabetic drug users between 2006 and 2018, from which we constructed 3 cohorts of new users of SGLT-2i, DPP-4i, and GLP-1 RA between 2016 and 2018. RESULTS: Our cohorts included 194,070 new users of DPP-4i, 166,722 new users of SGLT-2i, and 27,719 new users of GLP-1 RA. New users of GLP-1 RA were more likely to be younger (mean ± SD: 56.7 ± 12.2 years) than new users of DPP-4i (67.8 ± 12.3 years) or SGLT-2i (64.4 ± 11.1 years). In Canada, new users of DPP-4i were more likely to have a history of coronary artery disease (22%) than new users of SGLT-2i (20%) or GLP-1 RA (15%). CONCLUSION: line therapy for type 2 diabetes, important differences exist in the characteristics of users of these drugs. Contrary to existing guidelines, new users of DPP-4i had a higher prevalence of cardiovascular disease at baseline than new users of SGLT2i or GLP-1RA.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.022
Threshold uncertainty score0.159

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.006
Science and technology studies0.0020.001
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.245
Teacher spread0.228 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2022
Admission routes3
Has abstractyes

Explore more

Same venueBMC Endocrine DisordersSame topicDiabetes Treatment and ManagementFrench-language works237,207